Tyrosine Kinase 2 (TYK2) for GA and CS

Part of paid clinical trials in New Haven, Connecticut.

Sponsor
Yale University
Study ID
NCT06725264
Phase
PHASE2
Status
Withdrawn

Conditions

  • Granuloma Annulare
  • Sarcoidosis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

To investigate the role of an oral TYK2 inhibitor for the treatment of patients with moderate to severe sarcoidosis with cutaneous involvement (CSAMI score of 10 or greater) and GA (defined as a BSA involvement of at least 5%), which are difficult to treat.

Key Dates

Start date
Mar 31, 2025
Status verified
Apr 2025
Primary completion
Jun 30, 2026
Completion
Jun 30, 2026

Study Design

Enrollment
0 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Granuloma Annulare
    Participants with GA will receive the TYK2 inhibitor deucravacitinib 6mg twice daily
  • Experimental: Cutaneous Sarcoidosis
    Participants with CS will receive the TYK2 inhibitor deucravacitinib 6mg twice daily

Primary Outcome Measure

Percent change in the BSA involvement of GA [ Time Frame: Baseline and 6 months post-treatment ]

Locations (1)

FacilityCityStateZIPSite coordinators
YCCI/Church Street Research Unit (CSRU)New HavenConnecticut06519-

Find similar trials in New Haven, CT

By research site
YCCI/Church Street Research Unit (CSRU)· New Haven, CT

Related Studies